2011 - ISBTS 2011 Symposium


This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.

Oral Communications 12: Sensitization

14.233 - C1q-fixing antibodies in highly sensitised patients waiting for a small bowel transplant without the liver. The Oxford experience

Presenter: Anil, Vaidya, Oxford, United Kingdom
Authors: Suzanne Page2, Sue Fuggle2, Anil Vaidya1, Peter Friend1

233
C1q-fixing antibodies in highly sensitised patients waiting for a small bowel transplant without the liver. The Oxford experience

Suzanne Page2, Sue Fuggle2, Anil Vaidya1, Peter Friend1

1Department of Transplant surgery, Oxford Transplant Center, Oxford, United Kingdom; 2Department of Immunology, Oxford Transplant Center, Oxford, United Kingdom

Introduction: The consensus on transplanting against a positive cross match in a modified multivisceral or isolated intestinal graft recipient is still divided. In the interim, being a newly designated center, we err on the cautious side and do not transplant across a positive cross match. We analysed our data on the HLA-profiles of our patients on the waiting list using different parameters including the amount of C1-q fixing antibodies.

Patients and Materials: Waiting list patients were monitored regularly by solid phase assay using HLA single antigen beads. Calculated reaction frequencies (cRF) and median fluorescence intensity (MFI) were recorded. Furthermore cRF's were calculated for antibodies with an MFI of greater than 5000. In addition, C1q-fixing HLA antibodies were studied.

Results: From January 2009 to date, 5 patients were studied. Calculated reaction frequencies ranged from 99%-100%. cRF's for antibodies greater than 5000 (listed as unacceptable) was no different and these patients still remained highly sensitised with a cRF > 85%. However, cRF's calculated after eliminating complement fixing antibodies (by the C1q assay) significantly improved the cRF's in these patients. The range of cRF was reduced, ranging from 74%-0%. Interestingly all patients were negative for C1q-fixing Class II HLA antibodies. To determine how this change in cRf would benefit our patients all potential donor offers received between March 2011 and May 2011 were reviewed. The mean percentage of potential donors versus suitable donors improved significantly by 56% (range 22%-100%).

Conclusion: Access to a negative cross match transplant was significantly improved if only C1q-fixing antibodies were deemed as unacceptable. Incidentally, two patients from the list got offered a suitable matched organ. One patient got transplanted with a negative cross match and the other was not suitable due to non immunological reasons. Waiting for a negative cross match may be detrimental to the progression of the patients condition and therefore the importance of non-complement fixing donor specific antibodies should not be dismissed even though their relevance is unclear.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada